Deutsche Bank Starts BrightSpring Health (BTSG) at Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Deutsche Bank Starts BrightSpring Health (BTSG) at Hold
February 20, 2024 6:53 AM EST
UBS analyst AJ Rice initiates coverage on BrightSpring Health (NASDAQ: BTSG) with a Buy rating and a price target of $15.00.
The analyst comments "We initiate coverage of BrightSpring with a Buy rating and a $15 price target. Bottom line, BrightSpring offers attractive... More
February 20, 2024 5:15 AM EST
Wells Fargo initiates coverage on BrightSpring Health (NASDAQ: BTSG) with a Overweight rating and a price target of $15.00.
For an analyst ratings summary and ratings history on BrightSpring Health click here. For more ratings news on BrightSpring Health click here.
Shares of BrightSpring Health closed at $10.71 yesterday.
...
More
February 20, 2024 3:28 AM EST
Morgan Stanley analyst Erin Wright initiates coverage on BrightSpring Health (NASDAQ: BTSG) with a Overweight rating and a price target of $18.00.
The analyst commented: "BrightSpring's diversified healthcare services offering across both pharmacy and provider solutions offers multiple avenues for growth... More
February 20, 2024 2:46 AM EST
(Updated - February 20, 2024 3:47 AM EST)
Goldman Sachs analyst Jamie Perse initiates coverage on BrightSpring Health (NASDAQ: BTSG) with a Buy rating and a price target of $26.00.
The analyst said: "BTSG is a scaled national healthcare services company focused on providing pharmacy services and patient-level care to patients in the home and community settings.... More
February 20, 2024 2:26 AM EST
(Updated - February 20, 2024 3:54 AM EST)
Jefferies analyst Brian Tanquilut initiates coverage on BrightSpring Health (NASDAQ: BTSG) with a Buy rating and a price target of $18.00.
The analyst commented: "
BTSG Should See High-Single-Digit Organic EBITDA Growth, Driven Primarily by Tailwinds in Specialty Rx. We view BTSG as a healthy (+7% to +9%) organic growth story, and we see the bulk of this growth in its Specialty & Infusion segment (~50% of revs). The robust pipeline of new biotech drugs under development... More
